ScoreWhy is Realcan Pharmaceutical Group Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 2.78%
- The company has been able to generate a Return on Capital Employed (avg) of 2.78% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -23.71% and Operating profit at -146.74% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 2.68% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -23.71% and Operating profit at -146.74% over the last 5 years
4
Flat results in Sep 25
- NET PROFIT(HY) At CNY -2.03 MM has Grown at -118.21%
- NET SALES(HY) At CNY 3,649.88 MM has Grown at -9.6%
- RAW MATERIAL COST(Y) Grown by 5.97% (YoY)
5
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 2.02%, its profits have fallen by -98.6%
- At the current price, the company has a high dividend yield of 0.5
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Realcan Pharmaceutical Group Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Realcan Pharmaceutical Group Co., Ltd.
-100.0%
0.70
41.53%
China Shanghai Composite
15.17%
1.02
14.86%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-23.71%
EBIT Growth (5y)
-146.74%
EBIT to Interest (avg)
0.22
Debt to EBITDA (avg)
33.16
Net Debt to Equity (avg)
0.45
Sales to Capital Employed (avg)
0.60
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
80.29%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.78%
ROE (avg)
2.68%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
3132
Industry P/E
Price to Book Value
0.68
EV to EBIT
-146.29
EV to EBITDA
40.31
EV to Capital Employed
0.79
EV to Sales
0.86
PEG Ratio
NA
Dividend Yield
0.45%
ROCE (Latest)
-0.54%
ROE (Latest)
0.02%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
PRE-TAX PROFIT(Q)
At CNY 19.93 MM has Grown at 282.72%
NET PROFIT(HY)
Higher at CNY -2.03 MM
-13What is not working for the Company
NET PROFIT(HY)
At CNY -2.03 MM has Grown at -118.21%
NET SALES(HY)
At CNY 3,649.88 MM has Grown at -9.6%
RAW MATERIAL COST(Y)
Grown by 5.97% (YoY
Here's what is working for Realcan Pharmaceutical Group Co., Ltd.
Pre-Tax Profit
At CNY 19.93 MM has Grown at 282.72%
over average net sales of the previous four periods of CNY -10.91 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
Higher at CNY -2.03 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CNY MM)
Here's what is not working for Realcan Pharmaceutical Group Co., Ltd.
Net Profit
At CNY -2.03 MM has Grown at -118.21%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (CNY MM)
Net Sales
At CNY 3,649.88 MM has Grown at -9.6%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Raw Material Cost
Grown by 5.97% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
